Leave It To Beaver: Rozerem DTC Campaign Boosts New Rx Share
This article was originally published in The Pink Sheet Daily
Executive Summary
Takeda sleep aid’s new Rx share has grown more than 50% since campaign began.
You may also be interested in...
Rozerem DTC Ad Suggests Insomnia Drug Is Indicated In Children - FDA
Takeda's direct-to-consumer TV ad for the insomnia drug Rozerem (ramelteon) fails to disclose the drug's indication, does not include information related to side effects and suggests through "back to school"-themed images and statements that the drug is indicated in children, FDA says in a warning letter issued to the company March 5 and posted online March 8
Rozerem DTC Ad Suggests Insomnia Drug Is Indicated In Children – FDA
Agency issues an "untitled" letter to Takeda citing the 10-second TV spot.
Rozerem DTC Ad Suggests Insomnia Drug Is Indicated In Children – FDA
Agency issues an "untitled" letter to Takeda citing the 10-second TV spot.